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Ischemic stroke remains a heavy burden for industrialized countries. The only causal
therapy is the recanalization of occluded vessels via thrombolysis, which due to a
narrow time window still can be offered only to a minority of patients. Since the
majority of patients continues to exhibit neurological deficits even following successful
thrombolysis, restorative therapies are urgently needed that promote brain remodeling
and repair once stroke injury has occurred. Due to their unique properties of action,
stem cell-based strategies gained increasing interest during recent years. Using various
stroke models in both rodents and primates, the transplantation of stem cells, namely
of bone marrow derived mesenchymal stem cells (MSCs) or neural progenitor cells
(NPCs), has been shown to promote neurological recovery most likely via indirect
bystander actions. In view of promising observations, clinical proof-of-concept studies
are currently under way, in which effects of stem and precursor cells are evaluated
in human stroke patients. In this review we summarize already published studies,
which due to the broad experience in other medical contexts mostly employed
bone marrow-derived MSCs by means of intravenous transplantation. With the overall
number of clinical trials limited in number, only a fraction of these studies used
non-treated control groups, and only single studies were adequately blinded. Despite
these limitations, first promising results justify the need for more elaborate clinical
trials in order to make stem cell transplantation a success for stroke treatment in the
future.
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STEM AND PROGENITOR CELLS IN EXPERIMENTAL STROKE
MODELS
In defined areas of the adult brain such as the subgranular
zone of the dentate gyrus and the subventricular zone (SVZ) of
the lateral ventricles, endogenous neurogenesis persists during
adulthood (Alvarez-Buylla and Garcia-Verdugo, 2002; Taupin
and Gage, 2002; Silva-Vargas et al., 2013; Braun and Jessberger,
2014; Jessberger and Gage, 2014; Sawada et al., 2014). These
neurogenic niches comprise astrocyte like neural stem and pro-
genitor cells (NPC) that give rise to neurons under physio-
logic conditions (Doetsch et al., 1997, 1999). In rodent and
primate stroke models, cerebral ischemia stimulates endoge-
nous neurogenesis, and NPCs migrate from the SVZ towards
the site of injury where they proliferate and differentiate into
neurons (Liu et al., 1998; Arvidsson et al., 2002; Tonchev
et al., 2003; Yamashita et al., 2006). Unfortunately, both dif-
ferentiation and survival rates of endogenous NPCs are low
(Parent, 2003; Haas et al., 2005; Doeppner et al., 2009). For this
reason, the functional contribution of endogenous neurogene-
sis to post-ischemic neurological recovery remains a matter of
debate.
In view of their restorative properties, efforts have been made
to promote neurological recovery by transplantation of stem or
progenitor cells in ischemic stroke. Although embryonic stem cells
have the capacity to give rise to all cell lineages, their therapeu-
tic potential is limited due to teratoma formation and ethical
concerns (Blum and Benvenisty, 2008, 2009). Consequently, a
wide variety of adult stem and progenitor cells from different
species and various tissue sources have been used for therapeutic
purposes, which were transplanted either locally or systemically
in experimental models of focal cerebral ischemia (Bacigaluppi
et al., 2008, 2009; Schwarting et al., 2008; Bliss et al., 2010;
Zheng et al., 2010; Banerjee et al., 2012; Doeppner et al., 2012;
Leong et al., 2012). Although grafted cells are not thought to
be integrated into residing neural networks, they do promote
neurological recovery via paracrine (indirect) mechanisms that
involve the stimulation of endogenous angioneurogenesis and
neural plasticity, stabilization of the blood brain barrier as well as
modulation of peripheral and central immune responses (Doepp-
ner et al., 2012; Hermann and Chopp, 2012; Mora-Lee et al.,
2012; Zhang and Chopp, 2013). Despite the fact that questions
related to the optimal cell type, the most adequate cell delivery
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Table 1 | Clinical trials using stem cells or progenitor cells against stroke.
Authors Year Cell type Key findings
Bang et al. 2005 MSCs Cells were intravenously grafted twice within 9 weeks post-stroke. Better
outcome in Barthel index after 1 year, but no effect on NIHSS and MRI scan.
Lee et al. 2010 MSCs Intravenous cell grafting twice post-stroke with observation period of 5 years.
Better outcome in mRS.
Bhasin et al. 2011 MSCs Autologous intravenous MSC transplantation. Within 24 weeks, no signifi-
cant side effects observed plus putative increased neural plasticity.
Bhasin et al. 2013 MSCs Intravenous MSC transplantation followed by observation period of 24
weeks. Statistically improved modified Barthel Index and increased neural
plasticity after stem cell treatment. No side effects.
Honmou et al. 2011 MSCs Intravenous cell transplantation showed no side effects during 1 year of
follow-up. Reduction of lesion volume by >20% after 1 week.
Savitz et al. 2011 MSCs Intravenous transplantation of MSCs within 72 h post-stroke plus observa-
tion period of 6 months. No study-related side effects. Median NIHSS 13
before cell grafting and 3 after 6 months.
Barbosa da Fonseca et al. 2010 MSCs Intraarterial delivery of 99mTc-labeled MSCs. Significantly reduced intracere-
bral numbers of grafted cells after 24 h. No significant side effects for as long
as 120 days.
Moniche et al. 2012 MSCs Intraarterial infusion of MSCs between 5-9 days post-stroke. After 6 months,
no side effects but also no improved functional outcome.
Suárez-Monteagudo et al. 2009 MSCs Stereotactic transplantation of cells into 5 patients. Authors claim discrete
functional improvement after 1 year.
Kondziolka et al. 2000 Cultured neuronal cells Stereotactic delivery of cells with observation period of 18 months. Some
functional improvement. No relevant safety issues.
Kondziolka et al. 2005 Cultured neuronal cells Stereotactic cell delivery with maximal observation period of 24 months.
Some functional improvement, but primary outcome was not met. No
significant adverse events.
Savitz et al. 2005 Fetal lateral eminescence
(=neural) cells
Cells were pre-treated with anti-MHC I antibody and intracerebrally delivered.
Study was stopped after 5 patients. Significant side effects.
Rabinovich et al. 2005 Cell suspension from
immature nervous and
hemopoietic tissue
Intrathecal cell delivery in 10 patients. No significant side effects during 6
months of observation.
The table describes the studies quoted in the main text with special regard to key findings, the cell type used and the year of publication. MRI: magnetic resonance
imaging, mRS: modified Rankin Scale, MSCs: mesenchymal stem cells, NIHSS: National Institutes of Health Stroke Scale.
time point and the route of cell delivery are still vividly discussed,
clinical trials have been on the way with some of them holding
promising results. Due to the broad experience with these cells in
other clinical contexts, the most widely used cell source in clinical
stroke studies are mesenchymal stem cells (MSCs), which are
mostly derived from bone marrow. Besides, NPCs are also used
in stroke patients. The following paragraphs provide an overview
on major clinical trials (Table 1), which due to the existence of
multiple investigator-driven smaller trials by no means claims to
be exhaustive.
CLINICAL STROKE TRIALS USING STEM OR PROGENITOR
CELLS
MESENCHYMAL STEM CELL SOURCES
MSCs have been successfully used under various experimental
paradigms (Chen et al., 2001, 2003; Li et al., 2002; Kurozumi
et al., 2005; Ukai et al., 2007; Onda et al., 2008; Yoo et al.,
2008; Kranz et al., 2010; Sheikh et al., 2011). Due to the
long-lasting experience with MSC transplantation in other clin-
ical contexts, namely in malignancies of the blood, MSCs have
evolved as the preferred candidate for clinical transplantation
studies. Characteristics of MSCs include adherence on plastic
surfaces, expression of CD markers such as CD105, CD73 and
CD90 as well as differentiation into fat, bone and cartilage
tissue (Dominici et al., 2006). MSCs can be easily obtained
from various tissue sources including bone marrow and adi-
pose tissue (Bliss et al., 2007; Doeppner and Hermann, 2010).
They can also be easily expanded in vitro and are regarded to
be immunologically inert, which reduces the risk of rejection
of grafted cells in allogeneic transplantation settings (Aggarwal
and Pittenger, 2005; Beyth et al., 2005). Although MSCs can be
induced to differentiate into neural tissue in vitro (Pittenger et al.,
1999), their potential for neural differentiation is low. Never-
theless, transplantation of MSCs improves neurological outcome
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in experimental stroke models, which is attributed to paracrine
effects of grafted cells (Caplan, 2009). As such, promising pre-
clinical data lead to clinical studies using MSCs or bone marrow-
derived mononuclear progenitor cells (subsequently subsumed
together as MSCs), the most relevant of which are presented in
the next paragraph.
CLINICAL PROOF-OF-CONCEPT STUDIES USING MESENCHYMAL STEM
CELL TRANSPLANTATION
In one of the very first randomized controlled phase I/II clinical
trials, Bang et al. (2005) intravenously transplanted autologous
MSCs twice within 9 weeks after stroke onset. During the obser-
vation period of 1 year, patients receiving MSCs showed better
improvement of the Barthel Index than control patients, whereas
National Institutes of Health Stroke Scale (NIHSS) score and
brain injury assessed by magnetic resonance imaging (MRI)
did not differ between groups. Patient numbers in this trial
were low (5 MSC transplanted and 25 control patients), thus
possibly explaining the lack of significant results in the lat-
ter readouts. Taking this lack of statistical power and concerns
regarding the safety of fetal calf serum (Spees et al., 2004) that
was used for ex vivo MSC expansion into account, the same
study group performed an additional open-label and observer-
blinded clinical trial on patients suffering from severe strokes
using an observation period of 5 years (Lee et al., 2010). As
in their earlier study, MSCs were intravenously transplanted
twice in a total of 16 patients, whereas controls received no
injection. Although 4 patients from the MSC group died during
the observation period, no significant side effects or comor-
bidities attributed to the transplantation itself were observed.
Importantly, the modified Rankin Scale (mRS) score was signif-
icantly improved in patients receiving MSCs within the obser-
vation period. This improvement was associated with increased
levels of stromal cell-derived factor-1 that is upregulated upon
stroke in rodents and thought to be involved in MSC hom-
ing (Shen et al., 2007). Although Lee et al. (2010) significantly
extended the observation period to 5 years, more definite con-
clusions about the efficacy of MSCs cannot be drawn from this
study, which lacked randomization and true blinding. Inter-
estingly however, beneficial effects related to MSC treatment
seemed to correlate with the involvement of the SVZ into the
stroke. Thus, MSC transplantation was more effective when
the SVZ was not part of the evolving stroke lesion, suggest-
ing an indirect action of MSCs that promote endogenous neu-
roregeneration. According to a recent MRI study, the SVZ is
located in close proximity to stroke lesions in a large percent-
age of stroke patients. In a prospective cohort of 108 included
patients with first-ever stroke, the distance from the nearest
margin of the infarct to the SVZ was ≤2 mm in half of all
patients exhibiting visible diffusion weighted image (DWI) lesions
(Delavaran et al., 2013). Thus, the relationship between stroke
lesion and SVZ may represent a hitherto under-recognized factor
influencing responses to neurorestorative therapies (Lee et al.,
2010).
In the meantime, further clinical trials provided evidence
that intravenous MSC transplantation is safe and feasible in
humans (Bhasin et al., 2011, 2013; Honmou et al., 2011; Savitz
et al., 2011). However, scientific conclusions from these trials are
hampered due to the heterogeneous study design, the different
timing of cell delivery and considerable differences in size of
study groups. As a matter of fact, only two of the aforemen-
tioned studies included non-treated control groups (Bhasin et al.,
2011; Savitz et al., 2011). Nevertheless, these studies were not
randomized or blinded, and beneficial effects due to MSC trans-
plantation as described by Bhasin et al. therefore need further
evaluation.
Since the homing of MSCs and other stem cells into the brain
is limited after intravenous transplantation, a Brazilian group
performed intraarterial infusions of 99mTc-labeled MSCs in six
stroke patients with the aim of increasing the amount of grafted
cells within the brain (Barbosa da Fonseca et al., 2010). Although
significant cell homing was observed as early as 2 h post-stroke
within the ischemic hemisphere, the latter was greatly diminished
24 h post-stroke. Within an observation period of 120 days, no
significant side effects related to cell grafting were observed. Simi-
lar findings were reported by Battistella et al. (2011) for an obser-
vation period of 180 days after intraarterial MSC infusion during
the chronic phase of the stroke. Noteworthy, conclusions from the
aforementioned studies are limited by low patient numbers and a
lack of appropriate blinding. Since MSCs are known to home into
peripheral organs such as the lungs, questions remain about the
safety of required interventional procedures, particularly in more
severely affected patients suffering from serious comorbidities.
Patient safety will have to be taken into account carefully in future
treatment studies after a recent study did not observe a beneficial
effect of intraarterial MSC transplantation in patients suffering
from stroke (Moniche et al., 2012). In animal studies, intraarterial
MSC delivery was not superior to intravenous delivery (Yang
et al., 2013).
In an even smaller clinical study, Suarez-Monteagudo et al.
successfully transplanted autologous MSCs stereotactically into
the brain of five stroke patients, followed by an observation
period of 1 year (Suárez-Monteagudo et al., 2009). Although
the authors claimed a discrete functional improvement over
time, a scientific evaluation of this observation is certainly
misplaced due to the low patient number and the study trial
itself with no adequate control group. A sample of five patients
is even far too low to draw conclusions about therapeutic
safety. Reports of neurological improvement in small patient
cohorts are hampered by the fact that complication rates may
not be adequately determined. The MSC delivery into the
brain parenchyma should, if at all, be considered with great
caution.
At present, further studies that analyze both safety and feasi-
bility of MSCs in stroke patients are on the way. The U.S. National
Institutes of Health1 currently list 10 clinical trials ranging from
phases I to III upon the keywords “mesenchymal stem cells”
and “stroke”. The majority of these studies use intravenous cell
delivery with primary outcome measurements of either safety or
functional neurological improvement. However, the recruitment
status of these studies remains heterogeneous with some trials
having not yet recruited at all.
1www.clinicaltrials.gov
Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 357 | 3
Doeppner and Hermann Stem cells and clinical stroke trials
CRITICAL CONSIDERATIONS REGARDING MESENCHYMAL STEM CELL
TRANSPLANTATION IN HUMANS
Although clinical follow-up studies with observation periods
of one or 5 years did not show significant side effects (Bang
et al., 2005; Lee et al., 2010), safety issues carefully need to be
taken into account when considering MSCs for the treatment of
ischemic stroke. MSC treatment was associated with improved
outcome of stroke patients in at least some of the aforementioned
studies, suggesting that MSC transplantation is safe. Likewise, a
large meta-analysis on clinical trials under various pathological
conditions not exclusively related to stroke did not show any
evidence for severe side effects due to MSC transplantation (Lalu
et al., 2012). This work analyzed safety issues in 36 studies
covering a total of 1012 participants that had suffered from stroke,
Crohn’s disease, cardiomyopathy, myocardial infarction or graft
vs. host disease. Some studies also included MSC transplantation
in healthy non-affected volunteers. The meta-analysis did not
detect significant side effects related to MSC transplantation, such
as acute infusion-related toxicity, complications in peripheral
organ systems, infection, death, or tumor formation. There was,
however, a consistent observation of MSC transplantation-related
transient fever.
Nevertheless, setbacks and unfavorable reports in experi-
mental stroke models deserve special attention. Using intraar-
terial transplantation paradigms in a rat stroke model, Mitkari
et al. could not show improved functional outcome after MSC
transplantation, although grafted MSCs were attracted towards
the lesion site and post-ischemic angiogenesis was significantly
increased (Mitkari et al., 2014). In line with this, Steiner and
colleagues did not observe post-stroke neuroprotection after sys-
temic MSC transplantation in rodents, which was attributed to
homing of grafted MSCs into peripheral organs and not into
the brain (Steiner et al., 2012). Most importantly, transplantation
risks might increase when comorbidities such as diabetes are
taken into account. As such, Chen et al. did not show a beneficial
effect of MSCs in diabetic stroke rats, but even reported increased
mortality in treated animals that was associated with enhanced
brain hemorrhage as a consequence of maladaptive angiogenesis
(Chen et al., 2011).
Although MSCs themselves are not tumorigenic, they might
migrate to existing primary tumors and modify or even stim-
ulate tumor growth due to their immunomodulatory proper-
ties (Lazennec and Jorgensen, 2008). Accordingly, MSC-induced
bystander effects might change the biological behavior of tumor
cells with unpredictable consequences for the patient. Hence,
further clinical trials using larger study cohorts with extended
observation periods are urgently needed before more definite
conclusions about the safety of MSC transplantation may be
drawn. In view of risks related to invasive procedures, such studies
should preferably use intravenous instead of delivery strategies
from the authors’ point of view.
NEURAL STEM AND PROGENITOR CELLS AND OTHER STEM CELL
SOURCES
In comparison with MSCs, other cell types have been less
frequently evaluated in clinical studies. The hesitation of deliv-
ering these cells to human stroke patients is a consequence of
the fact that unlike MSCs, which are used for bone marrow
transplantation, these cells had not been used before as therapeu-
tics in other medical contexts. In case of NPCs, concerns remain
about malignant transformation, which cannot be ruled out
completely even when fetal or adult cell sources are used. NPCs
derived from the SVZ of the lateral ventricles induce potent neu-
roprotection and brain remodeling, both when systemically and
locally (i.e., intracerebrally) delivered. This aspect deserves special
attention, since cells are not integrated into neural networks
but act mainly via paracrine bystander mechanisms (Bacigaluppi
et al., 2008, 2009; Doeppner et al., 2010, 2012). Two clinical
trials have demonstrated the feasibility of stereotactic delivery of
cultured neuronal cells derived from a teratocarcinoma cell line
(Kondziolka et al., 2000, 2005). Although cell transplantation was
followed by some functional improvement, the primary outcome
measure of the study, the change in the European Stroke Scale
(ESS) motor score, was not met. Again, the sample size (4–7
patients per group) was too small to infer conclusions regarding
the therapeutic efficacy of NPC transplantation.
Another study using fetal porcine NPCs pre-treated with an
anti-MHC class I antibody for prevention of graft rejection could
not confirm its high expectations regarding safety and feasibility
(Savitz et al., 2005). Noteworthy, this trial was stopped after
intracerebral transplantation into five patients resulted in signif-
icant side effects in two patients. Thus, temporary worsening of
motor deficits was noted in one patient 3 weeks after transplan-
tation, while another patient developed epileptic seizures 1 week
after transplantation (Savitz et al., 2005). MRI in both patients
demonstrated areas of contrast enhancement remote from the
grafting site, which resolved on subsequent imaging. In contrast
to this study, another study investigating the intrathecal trans-
plantation of cell suspensions derived from immature nervous
and hematopoietic tissues did not detect any side effects in 10
patients over an observation period of 6 months (Rabinovich
et al., 2005). Although the number of published clinical studies
investigating cell sources other than MSCs is low, additional stud-
ies are on the way in stroke patients using cells from different tis-
sue sources. Among these ones, studies using genetically modified
NPCs are noteworthy, which are delivered by stereotactic intrac-
erebral transplantation (NCT02117635 and NCT01151124). In
other studies, human placenta-derived cells (NCT01310114) or
olfactory ensheathing cells (NCT01327768) are applied. While
the former study is already completed but not yet published,
the status of the latter is currently unknown.2 Unfortunately, the
aforementioned studies make use of intraparenchymal transplan-
tation strategies, which reduces their clinical relevance, even in
case they prove to be successful.
CONCLUSION AND OUTLOOK
Whereas application of stem cells has become a clinical routine for
treatment of hematological diseases, neurorestaurative treatment
paradigms using stem cells against stroke have not found their way
into the clinic, yet. However, first proof-of-concept studies eval-
uating MSC transplantation in human stroke patients achieved
promising data, which justify more systematic studies. These
2www.clinicaltrials.gov
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observations will have to be confirmed in larger cohorts in the
near future, before more definite conclusions regarding the safety
of stem cell treatment can be made. Unfortunately, recruitment
in some of the ongoing studies was rather slow in recent years,
which delays progress in the field of stem cell therapies. A major
problem of several previous studies is the lack of appropriate
control groups. On the other hand, clinical trials using cell sources
other than MSCs are still scarce and need further evaluation.
In the absence of clinical experience in larger patient cohorts,
questions of long-term safety remain a concern for most of the
latter cell sources, even when fetal or adult cells are used.
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